SGP (SpyGlass Pharma) Ending Cash Position: $223.14 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGP SpyGlass Pharma Inc SGP
12 GF Score
Price $25.07
View Full Analysis

What is SpyGlass Pharma Ending Cash Position?

SpyGlass Pharma SGP -0.59% 12 Ending Cash Position is $223.14 Mil as of Jun. 2026. GuruFocus rates SGP with a GF Score™ of 12/100.

SpyGlass Pharma's Ending Cash Position for the quarter that ended in Jun. 2026 was $223.14 Mil.

SpyGlass Pharma's quarterly Ending Cash Position increased from Dec. 2025 ($96.36 Mil) to Mar. 2026 ($238.90 Mil) but then declined from Mar. 2026 ($238.90 Mil) to Jun. 2026 ($223.14 Mil).

SpyGlass Pharma's annual Ending Cash Position increased from Dec. 2023 ($15.85 Mil) to Dec. 2024 ($16.27 Mil) and increased from Dec. 2024 ($16.27 Mil) to Dec. 2025 ($96.36 Mil).

SpyGlass Pharma Ending Cash Position Related Terms

SpyGlass Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for SpyGlass Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SpyGlass Pharma Ending Cash Position Chart

SpyGlass Pharma Annual Data
Trend Dec23 Dec24 Dec25
Ending Cash Position
15.85 16.27 96.36

SpyGlass Pharma Quarterly Data
Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial 127.24 106.01 96.36 238.90 223.14
SGP
12GF Score
SpyGlass Pharma Inc SGP
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SpyGlass Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

SpyGlass Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=16.268+80.09
=96.36

SpyGlass Pharma's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=238.902+-15.759
=223.14

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $223.14 Mil mean?
SpyGlass Pharma (SGP) has a Ending Cash Position of $223.14 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SpyGlass Pharma and its competitors.
Is SpyGlass Pharma's Ending Cash Position too high?
SpyGlass Pharma's current Ending Cash Position is $223.14 Mil. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's Ending Cash Position compare to RIGL and NGNE?
SpyGlass Pharma's Ending Cash Position of $223.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SpyGlass Pharma and its competitors. SpyGlass Pharma's current Ending Cash Position is $223.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current Ending Cash Position of $223.14 Mil. The current Ending Cash Position is $223.14 Mil. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current Ending Cash Position is $223.14 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SpyGlass Pharma Business Description

Address 27061 Aliso Creek Road, Suite 100, Aliso Viejo, CA, USA, 92656
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score

Get the complete analysis for SGP

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.07
Price